Arcutis Biotherapeutics
IPOMedical dermatology innovation
- Headquarters
- Westlake Village
- Employees
- 201–500
- Founded
- 2016
- Business Model
- B2B
- Website
- arcutis.com
- Total Funding
- $310.5M
- Last Round
- $150.0M Growth EquityFeb 2024
- Rounds
- 3
- Type
- Public
About
Arcutis Biotherapeutics (Nasdaq: ARQT) is a commercial-stage medical dermatology company focused on developing innovative topical treatments for immune-mediated skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Founded in 2016 by a leadership team with experience across 50+ FDA-approved products, the company applies recent advances in inflammation and immunology to bring best-in-class molecules against validated dermatologic targets. With six dermatology clinicians on staff, Arcutis prioritizes meaningful innovation to address urgent unmet needs in skin disease management.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...